A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR
Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 1, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a medication called Alendronate (ALN) can help improve knee function after surgery to repair a torn anterior cruciate ligament (ACL). The ACL is an important ligament that helps stabilize the knee, and injuries to it are very common. The trial aims to see if taking ALN can enhance knee stability, reduce bone loss around the surgery site, and improve overall knee function and strength over the course of 12 months. This study is currently looking for participants who are between 18 and 40 years old, are undergoing their first ACL surgery, and can attend pre-operative assessments.
If you decide to participate, you'll be randomly assigned to either receive ALN or not, and you won't know which group you're in (this is called a single-blind study). Throughout the year, researchers will monitor your knee function, muscle strength, and any symptoms you experience to see how well the treatment works. It's important to note that certain health conditions or recent surgeries may prevent someone from participating, so there are specific eligibility criteria to consider. Overall, this trial aims to find better ways to help patients recover from ACL surgery and reduce the chances of further knee problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female with age 18-40 at the time of surgery
- • First ACLR
- • Single leg involvement
- • Able to attend pre-operative assessment
- • Voluntarily agreed to participate and signed the informed consent form
- Exclusion Criteria:
- • Known chronic disease or receiving long-term medications affecting bone metabolism including BPs
- • Contraindication to alendronate therapy such as poor dental fitness
- • ACL injury less than 6 weeks
- • Injury on duty cases
- • Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months
- • Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)
- • Chondral lesion with concomitant intervention
- • Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts
- • Neurological deficit
- • Pregnant or breastfeeding
- • Inability to give informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials